[
  {
    "chunk_id": "acute_hyperglycemic_crisis__chunk0",
    "source_file": "data\\acute_hyperglycemic_crisis.txt",
    "title": "FILENAME: acute_hyperglycemic_crisis.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: acute_hyperglycemic_crisis.txt\nSUBJECT: DKA vs. HHS (Emergency Conditions)\n\n1. DIABETIC KETOACIDOSIS (DKA)\n-----------------------------------------------------------------------------\n* **Patient:** Mostly Type 1 (rarely Type 2).\n* **Mechanism:** Absolute lack of insulin. Body burns fat for fuel -> Ketones produced -> Blood becomes acidic.\n* **Onset:** Rapid (<24 hours).\n* **Signs:** Fruity breath, Kussmaul breathing (deep/fast), High Ketones, pH <7.3.\n\n2. HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)\n-----------------------------------------------------------------------------\n* **Patient:** Type 2 (usually elderly).\n* **Mechanism:** Severe dehydration and massive hyperglycemia (>600 mg/dL). There is just enough insulin to stop ketones, but not enough to lower sugar.\n* **Onset:** Gradual (days to weeks).\n* **Signs:** Profound dehydration, confusion/coma, NO Ketones.\n\n3. TREATMENT (HOSPITAL)\n-----------------------------------------------------------------------------\n* **Fluids:** Aggressive IV saline rehydration (Priority #1).\n* **Electrolytes:** Potassium replacement.\n* **Insulin:** IV insulin infusion (drip)."
  },
  {
    "chunk_id": "cardiovascular_diabetes_li__chunk0",
    "source_file": "data\\cardiovascular_diabetes_li.txt",
    "title": "FILENAME: cardiovascular_diabetes_link.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: cardiovascular_diabetes_link.txt\nSUBJECT: Macrovascular Complications\nSTATISTIC: CVD is the #1 cause of death in people with diabetes.\n\n1. THE MECHANISM\n-----------------------------------------------------------------------------\n* **Glycation:** Sugar sticks to LDL cholesterol, making it smaller and denser (\"small dense LDL\").\n* **Oxidation:** This sugar-coated LDL easily penetrates artery walls.\n* **Inflammation:** High sugar damages the endothelial lining of blood vessels, creating rough spots where plaque accumulates.\n* **Result:** Accelerated Atherosclerosis (hardening of arteries).\n\n2. ABCs OF HEART PROTECTION\n-----------------------------------------------------------------------------\n* **A1c:** Manage blood sugar.\n* **Blood Pressure:** Target <130/80 mmHg.\n* **Cholesterol:** Most diabetics over age 40 are recommended a Statin therapy regardless of cholesterol levels.\n* **Smoking:** Cessation is the single most effective intervention."
  },
  {
    "chunk_id": "cdc_type2_basics__chunk0",
    "source_file": "data\\cdc_type2_basics.txt",
    "title": "FILENAME: cdc_type2_basics.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: cdc_type2_basics.txt\nSOURCE: Centers for Disease Control and Prevention (CDC)\nSUBJECT: Type 2 Diabetes Mellitus - Basics, Risk, and Diagnosis\n\n1. WHAT IS TYPE 2 DIABETES? -----------------------------------------------------------------------------\nType 2 diabetes is a chronic condition that affects how the body processes \nblood sugar (glucose). * **Insulin Resistance:** The body does not use insulin properly. The \n    pancreas tries to make extra insulin to compensate, but eventually, it \n    cannot keep up, and blood sugar levels rise. * **Prevalence:** It accounts for approximately 90-95% of all diagnosed \n    cases of diabetes. 2. RISK FACTORS\n-----------------------------------------------------------------------------\nYou are at higher risk for developing Type 2 diabetes if you:\n\n* **Have Prediabetes:** Blood sugar is higher than normal but not yet high \n    enough to be diagnosed as diabetes. * **Are Overweight:** Being overweight or having obesity is a primary risk. * **Age:** Are age 45 or older. * **Family History:** Have a parent, brother, or sister with type 2 diabetes. * **Activity Level:** Are physically active less than 3 times a week. * **Gestational History:** Have ever had gestational diabetes (during \n    pregnancy) or gave birth to a baby who weighed over 9 pounds. * **Ethnicity:** Are African American, Hispanic/Latino, American Indian, \n    or Alaska Native. (Some Pacific Islanders and Asian Americans are also \n    at higher risk). 3. SYMPTOMS\n-----------------------------------------------------------------------------\nSymptoms often develop slowly over several years. Many people have no \nsymptoms until health problems occur. * Frequent urination (often at night). * Excessive thirst. * Unexplained weight loss. * Very hungry. * Blurry vision. * Numbness or tingling in hands or feet. * Feeling very tired (fatigue). * Very dry skin. * Sores that heal slowly. * More infections than usual. 4. DIAGNOSIS (A1C TEST)\n-----------------------------------------------------------------------------\nThe A1C test measures your average blood sugar level over the past 2 to 3 \nmonths. | Diagnosis    | A1C Level        |\n|--------------|------------------|\n| Normal       | Below 5.7%       |\n| Prediabetes  | 5.7% \u2013 6.4%      |\n| Diabetes     | 6.5% or higher   |\n\n*Note: Fasting Plasma Glucose (FPG) and Oral Glucose Tolerance Tests (OGTT) \nare also used for diagnosis.*\n\n5. PREVENTION & MANAGEMENT\n-----------------------------------------------------------------------------\nType 2 diabetes can often be prevented or delayed with lifestyle changes. A. Healthy Eating\n   - Focus on non-starchy vegetables (leafy greens, peppers, broccoli). - Choose whole grains over refined grains."
  },
  {
    "chunk_id": "cdc_type2_basics__chunk1",
    "source_file": "data\\cdc_type2_basics.txt",
    "title": "FILENAME: cdc_type2_basics.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "- Limit added sugars and refined carbohydrates. B. Physical Activity\n   - Goal: At least 150 minutes of moderate-intensity activity (like brisk \n     walking) per week. - Strength training 2 days a week is also recommended. C. Weight Loss\n   - Losing a modest amount of weight (5% to 7% of total body weight) can \n     significantly lower the risk. *Example: For a 200 lb person, this is a loss of 10-14 lbs.*\n\n6. COMPLICATIONS\n-----------------------------------------------------------------------------\nUncontrolled high blood sugar can lead to:\n* Heart disease and stroke. * Kidney disease (Chronic Kidney Disease). * Eye problems (Retinopathy, Cataracts, Glaucoma). * Nerve damage (Neuropathy). * Foot health issues (can lead to amputation if untreated). * Gum disease and dental problems. -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "diabetic_foot_care__chunk0",
    "source_file": "data\\diabetic_foot_care.txt",
    "title": "FILENAME: diabetic_foot_care.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: diabetic_foot_care.txt\nSUBJECT: Prevention of Ulcers and Amputation\nRISK FACTORS: Neuropathy (Loss of sensation) + PAD (Poor blood flow)\n\n1. THE \"DAILY INSPECTION\" PROTOCOL\n-----------------------------------------------------------------------------\nSince nerves may be damaged, pain is not a reliable warning sign. You must use your eyes.\n* **Check:** Bottoms of feet (use a mirror), between toes, and heels.\n* **Look for:** Cuts, blisters, redness, swelling, or ingrown nails.\n\n2. FOOTWEAR RULES\n-----------------------------------------------------------------------------\n* **Shake:** Shake out shoes before putting them on (a pebble could cause a wound you can't feel).\n* **Socks:** Wear white (to see blood/drainage) and seamless (to prevent rubbing) socks.\n* **No Barefoot:** Never walk barefoot, even indoors.\n\n3. HYGIENE\n-----------------------------------------------------------------------------\n* Wash feet daily in lukewarm water (test temp with elbow, not foot).\n* Dry thoroughly *between* the toes (moisture leads to fungal infection).\n* Apply lotion to tops and bottoms, but **never** between toes."
  },
  {
    "chunk_id": "diabetic_nephropathy__chunk0",
    "source_file": "data\\diabetic_nephropathy.txt",
    "title": "FILENAME: diabetic_nephropathy.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: diabetic_nephropathy.txt\nSUBJECT: Chronic Kidney Disease (CKD) in Diabetes\nTYPE: Microvascular Complication\n\n1. PATHOPHYSIOLOGY\n-----------------------------------------------------------------------------\n* **Hyperfiltration:** High blood sugar increases the pressure inside the kidney's filters (Glomeruli).\n* **Damage:** Over time, this high pressure damages the filtration barrier.\n* **Leakage:** Proteins (Albumin) that should stay in the blood start leaking into the urine.\n\n2. STAGES OF DAMAGE\n-----------------------------------------------------------------------------\n1.  **Microalbuminuria:** Small amounts of albumin in urine (30\u2013300 mg/day). Reversible.\n2.  **Macroalbuminuria:** Large amounts of albumin (>300 mg/day).\n3.  **Declining GFR:** The Glomerular Filtration Rate drops; waste builds up in blood.\n4.  **ESRD:** End-Stage Renal Disease requiring dialysis or transplant.\n\n3. MANAGEMENT\n-----------------------------------------------------------------------------\n* **BP Control:** Strict blood pressure control (<130/80).\n* **ACE Inhibitors / ARBs:** (e.g., Lisinopril, Losartan). These drugs dilate the efferent arteriole, lowering pressure *inside* the kidney.\n* **SGLT2 Inhibitors:** Proven to slow the progression of CKD."
  },
  {
    "chunk_id": "diabetic_retinopathy__chunk0",
    "source_file": "data\\diabetic_retinopathy.txt",
    "title": "FILENAME: diabetic_retinopathy.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: diabetic_retinopathy.txt\nSUBJECT: Diabetic Retinopathy (Eye Disease)\nTYPE: Microvascular Complication\nSEVERITY: Leading cause of blindness in working-age adults (20-74). 1. OVERVIEW\n-----------------------------------------------------------------------------\nDiabetic Retinopathy damages the blood vessels of the light-sensitive tissue \nat the back of the eye (retina). It is a progressive condition directly linked \nto the duration of diabetes and the severity of hyperglycemia. 2. PATHOPHYSIOLOGY (THE MECHANISM OF LEAKAGE)\n-----------------------------------------------------------------------------\nThe retina has the highest metabolic rate (oxygen consumption) of any tissue \nin the body. It relies on a delicate network of capillaries. A. Pericyte Loss (The First Domino)\n   * Capillaries are supported by cells called \"pericytes\" that wrap around \n     them like a structural wall. * High blood sugar triggers apoptosis (cell death) of these pericytes. * **Result:** The vessel walls weaken and balloon out, forming \n     **Microaneurysms**. B. Ischemia and Hypoxia\n   * Capillaries eventually become blocked by thickened basement membranes. * The retina becomes \"hypoxic\" (starved of oxygen). * **Cotton Wool Spots:** White, fluffy patches appear on the retina, \n     signaling areas of nerve fiber infarction (death due to lack of blood). C. The VEGF Response (The Fatal Flaw)\n   * The oxygen-starved retina sends out a distress signal: **Vascular \n     Endothelial Growth Factor (VEGF)**. * VEGF commands the eye to grow *new* blood vessels to supply oxygen. * **The Problem:** These new vessels (Neovascularization) are fragile, \n     abnormal, and leaky. They rupture easily, bleeding into the eye. 3. STAGES OF PROGRESSION\n-----------------------------------------------------------------------------\n\nA. Non-Proliferative Diabetic Retinopathy (NPDR)\n   * **\"Background Retinopathy\"**\n   * Blood vessels are damaged but new ones haven't started growing yet. * Vessels leak fluid and lipids into the retina. * **Hard Exudates:** Yellow deposits of lipid/protein leaked from vessels. * Vision is usually fine unless fluid accumulates in the macula. B. Proliferative Diabetic Retinopathy (PDR)\n   * **\"Advanced Retinopathy\"**\n   * VEGF has triggered the growth of fragile new blood vessels on the surface \n     of the retina and into the vitreous gel. * **Risks:** 1. Vitreous Hemorrhage (bleeding into the jelly of the eye). 2. Tractional Retinal Detachment (scar tissue pulls the retina off the \n        back of the eye). 4. SPECIFIC COMPLICATION: DIABETIC MACULAR EDEMA (DME)\n-----------------------------------------------------------------------------\n* Can occur at *any* stage (NPDR or PDR). * Fluid builds up in the **Macula** (the center part of the retina responsible \n  for sharp, straight-ahead vision)."
  },
  {
    "chunk_id": "diabetic_retinopathy__chunk1",
    "source_file": "data\\diabetic_retinopathy.txt",
    "title": "FILENAME: diabetic_retinopathy.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "* **Symptom:** Objects look wavy or blurry; colors look washed out. 5. SYMPTOMS\n-----------------------------------------------------------------------------\nEarly stages are often asymptomatic (silent). As it advances:\n* \"Floaters\" (dark strings floating in vision - usually blood). * Blurred or fluctuating vision. * Dark or empty areas in your vision. * Difficulty seeing at night. 6. TREATMENTS\n-----------------------------------------------------------------------------\n* **Anti-VEGF Injections:** Drugs (like ranibizumab or aflibercept) are \n  injected directly into the eye to block the VEGF signal, stopping abnormal \n  vessel growth. * **Photocoagulation (Laser Surgery):**\n  - *Focal Laser:* Seals specific leaking vessels. - *Scatter Laser (Panretinal):* Shrinks abnormal blood vessels by making \n    tiny burns across the peripheral retina. * **Vitrectomy:** Surgical removal of blood-filled vitreous gel. -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "glp1_drugs_overview__chunk0",
    "source_file": "data\\glp1_drugs_overview.txt",
    "title": "FILENAME: glp1_drugs_overview.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: glp1_drugs_overview.txt\nSUBJECT: GLP-1 Receptor Agonists (Incretin Mimetics)\nCLASS: Glucagon-like Peptide-1 Agonists\nCOMMON BRANDS: Ozempic, Wegovy, Trulicity, Victoza, Mounjaro (Dual agonist)\n\n1. OVERVIEW\n-----------------------------------------------------------------------------\nGLP-1 Receptor Agonists are a class of non-insulin injectable medications \n(though an oral version exists). They mimic the action of the natural hormone \nGLP-1, which is released from the gut in response to eating. * **Key Characteristic:** Their action is \"Glucose-Dependent.\" They only \n  stimulate insulin when blood sugar is high, making the risk of dangerous \n  hypoglycemia very low compared to insulin or sulfonylureas. 2. MECHANISM OF ACTION (THE MULTI-ORGAN EFFECT)\n-----------------------------------------------------------------------------\nThese drugs do not just lower sugar; they alter how the body manages energy \nintake and processing across four key organs. A. The Pancreas (The Dual Switch)\n   * **Insulin:** Stimulates beta-cells to release insulin *only* when glucose \n     levels are elevated. * **Glucagon:** Suppresses the release of glucagon (the hormone that raises \n     blood sugar) from alpha-cells. B. The Stomach (The \"Brake\")\n   * **Delayed Gastric Emptying:** Slows down the speed at which food leaves \n     the stomach. * **Result:** This flattens the post-meal blood sugar spike and physically \n     signals fullness to the brain. C. The Brain (The Appetite Control Center)\n   * GLP-1 receptors are present in the hypothalamus (hunger center). * **Satiety:** These drugs directly stimulate the feeling of \"fullness.\"\n   * **Cravings:** They reduce the \"food noise\" (intrusive thoughts about \n     food) and reward-seeking behavior associated with eating. D. The Liver\n   * Because glucagon is suppressed, the liver reduces its output of stored \n     glucose (Gluconeogenesis). 3. CLASSIFICATION AND EVOLUTION\n-----------------------------------------------------------------------------\nThe class has evolved from twice-daily injections to weekly injections with \nhigher potency."
  },
  {
    "chunk_id": "glp1_drugs_overview__chunk1",
    "source_file": "data\\glp1_drugs_overview.txt",
    "title": "FILENAME: glp1_drugs_overview.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "| Generation | Generic Name | Brand Examples | Frequency | Primary Focus |\n| :--- | :--- | :--- | :--- | :--- |\n| **First** | Exenatide | Byetta | Twice Daily | Diabetes Control |\n| **Second** | Liraglutide | Victoza / Saxenda | Daily | Diabetes & Weight |\n| **Third** | Dulaglutide | Trulicity | Weekly | Diabetes Control |\n| **Fourth** | Semaglutide | Ozempic / Wegovy | Weekly | High Potency Weight & Diabetes |\n| **Next Gen**| Tirzepatide*| Mounjaro / Zepbound | Weekly | *Dual Agonist (GLP-1 + GIP) |\n\n* *Note: Tirzepatide is technically a dual agonist, activating both GLP-1 and \n  GIP receptors, leading to even greater efficacy.*\n\n4. CLINICAL BENEFITS\n-----------------------------------------------------------------------------\n* **A1C Reduction:** Highly effective, typically lowering A1C by 1.0% to 2.0%. * **Weight Loss:**\n  - Semaglutide: ~15% body weight loss in clinical trials. - Tirzepatide: Up to ~20%+ body weight loss. * **Cardiovascular Protection:** Many agents in this class (Semaglutide, \n  Liraglutide) have FDA indications for reducing the risk of heart attack \n  and stroke in people with heart disease. 5. SIDE EFFECTS AND RISKS\n-----------------------------------------------------------------------------\nA. Gastrointestinal (The Most Common)\n   * Nausea, vomiting, and diarrhea affect a significant portion of users. * **Mechanism:** Caused by the slowing of the stomach (gastroparesis effect). * **Management:** Usually transient. Mitigated by starting at a low dose \n     and \"titrating\" (increasing) slowly over months. B. Rare / Serious Warnings\n   * **Pancreatitis:** Risk of inflammation of the pancreas. * **Gallbladder Disease:** Rapid weight loss can lead to gallstones. * **Thyroid C-Cell Tumors:** Black Box Warning based on rodent studies \n     (risk in humans is not confirmed but contraindicated in those with a \n     family history of MTC). -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "glucose_monitoring_steps__chunk0",
    "source_file": "data\\glucose_monitoring_steps.txt",
    "title": "FILENAME: glucose_monitoring_steps.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: glucose_monitoring_steps.txt\nSUBJECT: Self-Monitoring of Blood Glucose (SMBG)\nMETHOD: Capillary Blood Glucose Test (Finger Stick)\n\n1. HOW THE TECHNOLOGY WORKS (THE STRIP MECHANISM)\n-----------------------------------------------------------------------------\nThe test strip is not just a piece of plastic; it is a mini-electrochemical \ncell. A. The Enzyme Layer\n   * The tip of the strip contains an enzyme, typically **Glucose Oxidase** or **Glucose Dehydrogenase**. * When blood hits the strip, the enzyme reacts with the glucose in the \n     blood to produce Gluconic Acid. B. The Electrical Current (Amperometry)\n   * This chemical reaction releases electrons. * The meter applies a small voltage to the strip. * The moving electrons create an electrical current. * **The Calculation:** The strength of the current is directly proportional \n     to the amount of glucose in the sample. The meter calculates this and \n     displays the number. 2. PREPARATION (CRITICAL FOR ACCURACY)\n-----------------------------------------------------------------------------\nA. Wash and Dry Hands\n   * **Must do:** Use warm water and soap. * **Why:** Sugar residue on fingers (from fruit, lotion, or dirt) will \n     mix with the blood drop and cause a falsely high reading. * **Dry Thoroughly:** Water dilutes the blood sample, causing a falsely \n     low reading. B. Prepare the Lancet Device\n   * Insert a new, sterile lancet (needle) into the lancing device. * **Depth Setting:** Adjust the depth gauge. - Thin skin/children: 1-2\n     - Average skin: 3-4\n     - Calloused/thick skin: 5\n\n3. THE PROCEDURE (STEP-BY-STEP)\n-----------------------------------------------------------------------------\n1. **Load the Strip:** Insert the test strip into the meter. Wait for the \n   \"drop\" icon to appear. 2. **Select the Site:** * Do NOT prick the fleshy pad (center) of the fingertip. It has the most \n     nerve endings and hurts the most. * **Target:** The sides of the fingertip (lateral aspect). 3. **Stimulate Flow:** Massage the finger from the palm toward the tip to \n   encourage blood flow. 4. **Lance:** Place the device firmly against the side of the finger and \n   press the button. 5. **The Drop:** Squeeze gently to get a round drop of blood. * *Pro-Tip:* Wipe away the very first drop with a tissue (it may contain \n     interstitial fluid) and use the second drop for the most accuracy (though \n     modern meters often accept the first drop). 6. **Application:** Touch the *tip* of the strip to the blood drop."
  },
  {
    "chunk_id": "glucose_monitoring_steps__chunk1",
    "source_file": "data\\glucose_monitoring_steps.txt",
    "title": "FILENAME: glucose_monitoring_steps.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "Do not \n   drip blood *on top* of the strip; let the strip sip it up via capillary action. 7. **Clean Up:** Apply pressure to the finger with a tissue. Dispose of the \n   lancet in a sharps container. 4. INTERPRETING THE DATA (ADA TARGETS)\n-----------------------------------------------------------------------------\nTarget ranges vary by individual, but standard goals for non-pregnant adults are:\n\n| Timing              | Target Range (mg/dL) | Target Range (mmol/L) |\n|---------------------|----------------------|-----------------------|\n| Fasting (Pre-meal)  | 80 \u2013 130 mg/dL       | 4.4 \u2013 7.2 mmol/L      |\n| Postprandial (2hrs) | Less than 180 mg/dL  | Less than 10.0 mmol/L |\n\n5. COMMON ERROR CODES & CAUSES\n-----------------------------------------------------------------------------\n* **Not enough blood:** The strip didn't fill completely. * **Expired strips:** Enzymes degrade over time and with humidity. * **Temperature:** Meter is too hot or too cold (must be at room temp). * **Contamination:** \"Sugar fingers\" (unwashed hands). 6. ALTERNATIVE: CONTINUOUS GLUCOSE MONITORING (CGM)\n-----------------------------------------------------------------------------\n* **How it works:** A tiny filament sits under the skin (usually arm or belly) \n  measuring glucose in the *interstitial fluid* (fluid between cells), not \n  the blood. * **Lag Time:** Interstitial glucose lags behind blood glucose by ~10-15 \n  minutes. Finger sticks are still required to verify sudden highs or lows. -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "glycemic_index_load__chunk0",
    "source_file": "data\\glycemic_index_load.txt",
    "title": "FILENAME: glycemic_index_load.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: glycemic_index_load.txt\nSUBJECT: Nutritional Metrics for Carbohydrate Management\n\n1. GLYCEMIC INDEX (GI) - THE \"SPEED\"\n-----------------------------------------------------------------------------\n* **Definition:** Measures how *fast* a food raises blood sugar compared to pure glucose (Scale 0-100).\n* **Low GI (<55):** Beans, fibrous veggies, nuts.\n* **High GI (>70):** White bread, watermelon, instant oats.\n* **Flaw:** Doesn't account for portion size. (Watermelon has high GI, but low carb density).\n\n2. GLYCEMIC LOAD (GL) - THE \"IMPACT\"\n-----------------------------------------------------------------------------\n* **Definition:** (GI x Grams of Carbs) / 100. This measures the actual impact of a typical serving size.\n* **The Better Metric:** GL is more useful for real-world eating.\n\n3. COMPARISON EXAMPLE\n-----------------------------------------------------------------------------\n* **Watermelon:**\n    * GI = 72 (High - absorbs fast).\n    * Carbs per serving = 6g.\n    * GL = 4 (Low impact). *Safe in moderation.*\n* **Bagel:**\n    * GI = 72 (High).\n    * Carbs per serving = 50g.\n    * GL = 36 (Massive impact). *Avoid.*"
  },
  {
    "chunk_id": "hypoglycemia_protocol__chunk0",
    "source_file": "data\\hypoglycemia_protocol.txt",
    "title": "FILENAME: hypoglycemia_protocol.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: hypoglycemia_protocol.txt\nSUBJECT: Management of Hypoglycemia (Low Blood Sugar)\nTHRESHOLD: <70 mg/dL (<3.9 mmol/L)\n\n1. SYMPTOMS\n-----------------------------------------------------------------------------\n* **Adrenergic (Early):** Shaking, sweating, rapid heartbeat, anxiety.\n* **Neuroglycopenic (Late):** Confusion, slurred speech, blurry vision, drowsiness.\n\n2. THE \"15-15 RULE\" (STANDARD PROTOCOL)\n-----------------------------------------------------------------------------\n1.  **Check:** If blood glucose is <70 mg/dL.\n2.  **Treat:** Consume **15 grams** of fast-acting carbohydrates.\n    * 4 glucose tablets.\n    * 4 ounces (1/2 cup) of juice or regular soda.\n    * 1 tablespoon of sugar or honey.\n3.  **Wait:** Wait **15 minutes**.\n4.  **Re-check:** If still <70 mg/dL, repeat the 15g carbs.\n5.  **Stabilize:** Once normal, eat a small snack with protein (e.g., crackers and cheese) to prevent a drop.\n\n3. EMERGENCY PROTOCOL (UNCONSCIOUS PATIENT)\n-----------------------------------------------------------------------------\n* **Do NOT:** Give food or drink (choking hazard).\n* **Glucagon:** Administer Glucagon injection or nasal powder (Baqsimi).\n    * *Mechanism:* Signals the liver to dump stored glycogen into the blood immediately.\n* **Call 911:** If the patient does not wake up within 15 minutes."
  },
  {
    "chunk_id": "insulin_resistance__chunk0",
    "source_file": "data\\insulin_resistance.txt",
    "title": "FILENAME: insulin_resistance.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: insulin_resistance.txt\nSUBJECT: Pathophysiology of Insulin Resistance (IR)\nCONDITION: Precursor to Type 2 Diabetes / Metabolic Syndrome\n\n1. OVERVIEW\n-----------------------------------------------------------------------------\nInsulin Resistance (IR) is a pathological state where insulin-sensitive cells \n(primarily in muscle, fat, and liver) fail to respond appropriately to normal \nlevels of insulin. * **The Compensation:** To overcome this resistance, the beta cells of the \n  pancreas secrete increasing amounts of insulin (Hyperinsulinemia). * **The Tipping Point:** When the pancreas can no longer sustain this increased \n  output, blood glucose levels rise, leading to Prediabetes and Type 2 Diabetes. 2. MOLECULAR MECHANISM (THE \"BROKEN SIGNAL\")\n-----------------------------------------------------------------------------\nUnder normal conditions, insulin acts like a key unlocking a cell to let glucose \nin. In IR, the lock is jammed. A. The Normal Pathway (Simplified)\n   1. Insulin binds to the Insulin Receptor (IR) on the cell surface. 2. This triggers the phosphorylation of Insulin Receptor Substrate (IRS) \n      molecules (specifically Tyrosine phosphorylation). 3. This activates the PI3K-Akt signaling pathway. 4. **Result:** GLUT4 transporters move to the cell surface to intake glucose. B. The Defect (Where it breaks)\n   The core defect often lies in \"post-receptor signaling.\"\n   \n   * **Serine Phosphorylation:** Excess free fatty acids and inflammatory \n     cytokines (like TNF-alpha) cause the IRS proteins to be phosphorylated \n     at *Serine* residues instead of *Tyrosine*. * **The Block:** This \"incorrect\" phosphorylation inhibits the signal. The \n     message never reaches the interior of the cell. * **Lipotoxicity:** Accumulation of lipid metabolites (DAGs and Ceramides) \n     inside muscle and liver cells physically interferes with insulin signaling. 3. PHYSIOLOGICAL EFFECTS (SYSTEMIC LEVEL)\n-----------------------------------------------------------------------------\nDifferent tissues react to resistance in different ways, creating a \"perfect storm\" \nfor high blood sugar. A. Skeletal Muscle (The Major Consumer)\n   * Normally absorbs ~80% of post-meal glucose. * **In Resistance:** GLUT4 transporters fail to translocate to the surface. Glucose remains trapped in the bloodstream. B. The Liver (The Producer)\n   * Normally, insulin signals the liver to STOP making sugar (gluconeogenesis) \n     after a meal. * **In Resistance:** The liver ignores the signal and continues pumping \n     glucose into the blood, even when blood sugar is already high. C. Adipose Tissue (Fat Cells)\n   * Normally, insulin prevents the breakdown of stored fat. * **In Resistance:** Fat cells release excessive Free Fatty Acids (FFAs) into \n     circulation."
  },
  {
    "chunk_id": "insulin_resistance__chunk1",
    "source_file": "data\\insulin_resistance.txt",
    "title": "FILENAME: insulin_resistance.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "These FFAs travel to the muscle and liver, worsening the \n     resistance (a vicious cycle). 4. CLINICAL SIGNS & SYMPTOMS\n-----------------------------------------------------------------------------\nInsulin resistance is often \"silent\" until metabolic damage occurs, but specific \nsigns exist:\n\n* **Acanthosis Nigricans:** Dark, velvety patches of skin (neck, armpits, groin). * **Skin Tags:** Numerous small fleshy growths. * **Abdominal Obesity:** High visceral fat (waist circumference >40\" men, >35\" women). * **High Triglycerides / Low HDL:** A specific dyslipidemia profile. * **Polycystic Ovary Syndrome (PCOS):** IR is a primary driver of PCOS in women. 5. ETIOLOGY (CAUSES)\n-----------------------------------------------------------------------------\n* **Visceral Adiposity:** Belly fat is metabolically active, releasing inflammatory \n  markers that block insulin signals. * **Sedentary Lifestyle:** Muscle inactivity reduces insulin sensitivity. * **Diet:** Chronic excess of refined carbohydrates and saturated fats. * **Genetics:** Strong hereditary component (e.g., TCF7L2 gene variants). -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "insulin_therapy_types__chunk0",
    "source_file": "data\\insulin_therapy_types.txt",
    "title": "FILENAME: insulin_therapy_types.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: insulin_therapy_types.txt\nSUBJECT: Pharmacokinetics of Insulin Preparations\nUSAGE: Basal-Bolus Regimens\n\n1. RAPID-ACTING (BOLUS)\n-----------------------------------------------------------------------------\n* **Examples:** Lispro (Humalog), Aspart (Novolog), Glulisine (Apidra).\n* **Role:** Covers the glucose spike from meals.\n* **Onset:** 15 minutes.\n* **Peak:** 1 hour.\n* **Duration:** 2\u20134 hours.\n* **Timing:** Taken immediately before eating.\n\n2. SHORT-ACTING (REGULAR)\n-----------------------------------------------------------------------------\n* **Examples:** Humulin R, Novolin R.\n* **Role:** Older generation meal coverage (often used in IV drips for DKA).\n* **Onset:** 30 mins.\n* **Peak:** 2\u20133 hours.\n* **Duration:** 3\u20136 hours.\n\n3. INTERMEDIATE-ACTING (NPH)\n-----------------------------------------------------------------------------\n* **Examples:** Humulin N, Novolin N.\n* **Appearance:** Cloudy.\n* **Role:** Covers basal needs for half the day (often twice daily).\n* **Peak:** 4\u201312 hours (High risk of nocturnal hypoglycemia).\n\n4. LONG-ACTING (BASAL)\n-----------------------------------------------------------------------------\n* **Examples:** Glargine (Lantus), Detemir (Levemir).\n* **Role:** Keeps blood sugar stable between meals and overnight.\n* **Onset:** 2\u20134 hours.\n* **Peak:** None (Peakless/Flat profile).\n* **Duration:** 24 hours.\n\n5. ULTRA-LONG ACTING\n-----------------------------------------------------------------------------\n* **Examples:** Degludec (Tresiba), Glargine U-300 (Toujeo).\n* **Duration:** >42 hours.\n* **Benefit:** Allows flexibility in injection timing."
  },
  {
    "chunk_id": "metformin_mechanism__chunk0",
    "source_file": "data\\metformin_mechanism.txt",
    "title": "FILENAME: metformin_mechanism.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: metformin_mechanism.txt\nSUBJECT: Pharmacological Mechanism of Action: Metformin\nCLASS: Biguanide\n\n1. OVERVIEW\n-----------------------------------------------------------------------------\nMetformin is the first-line pharmacotherapy for the treatment of Type 2 Diabetes \nMellitus (T2DM). It is an antihyperglycemic agent that lowers basal and \npostprandial plasma glucose. Unlike sulfonylureas, it does not stimulate \ninsulin secretion, meaning it rarely causes hypoglycemia. 2. MOLECULAR MECHANISM (CELLULAR LEVEL)\n-----------------------------------------------------------------------------\nThe primary site of action is the hepatocyte (liver cell), specifically within \nthe mitochondria. A. Mitochondrial Inhibition (The Primary Trigger)\n   - Metformin enters the hepatocyte via Organic Cation Transporter 1 (OCT1). - Inside the mitochondria, Metformin inhibits Complex I of the Electron \n     Transport Chain (ETC). - This inhibition reduces the efficiency of oxidative phosphorylation. B. The Energy Crisis (ATP Reduction)\n   - Because the ETC is inhibited, ATP production drops. - This leads to an increase in cellular AMP (Adenosine Monophosphate) and \n     ADP relative to ATP. - Result: A significant rise in the AMP:ATP ratio. C. Activation of AMPK (The Classical Pathway)\n   - The high AMP levels activate Adenosine Monophosphate-Activated Protein \n     Kinase (AMPK). - AMPK acts as a cellular \"fuel gauge.\" When activated, it triggers \n     catabolic pathways (generating energy) and inhibits anabolic pathways \n     (consuming energy). - Crucially, AMPK phosphorylation creates a \"switch\" that turns off genes \n     responsible for Gluconeogenesis (production of glucose). D. Inhibition of mGPD (The Non-AMPK Pathway)\n   - Metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase (mGPD). - This prevents the conversion of glycerol into glucose precursors, halting \n     gluconeogenesis independently of insulin signaling. 3. PHYSIOLOGICAL EFFECTS (SYSTEMIC LEVEL)\n-----------------------------------------------------------------------------\n\nA. Hepatic (Liver) - *Most Important Effect*\n   - Suppression of Gluconeogenesis: Reduces the liver's production of glucose \n     from lactate, glycerol, and amino acids. - Suppression of Glycogenolysis: Reduces the breakdown of stored glycogen \n     into glucose. B. Peripheral (Muscle and Fat)\n   - Increases insulin sensitivity. - Enhances peripheral glucose uptake (mostly in muscle tissue) by inducing \n     GLUT4 transporter translocation to the cell membrane. - Increases fatty acid oxidation (burning fat for fuel). C. Gastrointestinal (Gut)\n   - Delayed Glucose Absorption: Slows the absorption of glucose from the \n     intestines. - GLP-1 Secretion: Increases the secretion of Glucagon-like peptide-1 \n     (GLP-1), an incretin hormone that improves insulin release and suppresses \n     appetite. - Microbiome Alteration: Modifies gut bacteria composition, which may \n     contribute to improved metabolic profiles. 4."
  },
  {
    "chunk_id": "metformin_mechanism__chunk1",
    "source_file": "data\\metformin_mechanism.txt",
    "title": "FILENAME: metformin_mechanism.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "CLINICAL OUTCOMES\n-----------------------------------------------------------------------------\n* Reduction of HbA1c (typically by 1.0% - 1.5%). * Weight neutral or modest weight loss. * Improved lipid profile (lowered LDL and triglycerides). * Potential cardiovascular protection (cardioprotective effects beyond \n    glucose lowering). -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "neuropathy_overview__chunk0",
    "source_file": "data\\neuropathy_overview.txt",
    "title": "FILENAME: neuropathy_overview.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: neuropathy_overview.txt\nSUBJECT: Diabetic Neuropathy (Nerve Damage)\nTYPE: Microvascular Complication\nPREVALENCE: Affects ~50% of patients with long-standing diabetes. 1. OVERVIEW\n-----------------------------------------------------------------------------\nDiabetic Neuropathy is a type of nerve damage that can occur if you have \ndiabetes. High blood sugar (hyperglycemia) injures nerves throughout the body. It most often damages nerves in the legs and feet. 2. PATHOPHYSIOLOGY (THE MECHANISM OF DAMAGE)\n-----------------------------------------------------------------------------\nWhy does sugar destroy nerves? There are two primary theories:\n\nA. The Vascular Hypothesis (Ischemia)\n   * Nerves need their own blood supply to survive, provided by tiny vessels \n     called the **Vasa Nervorum**. * High blood sugar damages these tiny vessels (microangiopathy), thickening \n     the vessel walls and reducing blood flow. * **Result:** The nerves \"starve\" from a lack of oxygen and nutrients. B. The Metabolic Hypothesis (The Polyol Pathway)\n   * Normally, cells use glucose for energy. * When glucose is too high, it floods an alternate pathway called the \n     **Polyol Pathway**. * The enzyme *Aldose Reductase* converts excess glucose into **Sorbitol**. * **The Problem:** Sorbitol cannot exit the cell easily. It accumulates, \n     drawing water into the nerve cell (osmotic stress) and depleting \n     antioxidants (NADPH). * **Result:** The nerve cell swells and suffers oxidative damage. 3. MAJOR TYPES OF NEUROPATHY\n-----------------------------------------------------------------------------\n\nA. Peripheral Neuropathy (Distal Symmetric Polyneuropathy)\n   * **Most Common Form.**\n   * **Pattern:** \"Stocking-glove\" distribution. It starts at the longest \n     nerves (toes) and slowly moves up the legs. Later, it affects the fingertips \n     and hands. * **Symptoms:** Numbness, tingling, burning sensation, sharp pains, or loss \n     of ability to feel pain/temperature (high risk for foot ulcers). B. Autonomic Neuropathy\n   * Affects the nerves that control internal organs (involuntary functions). * **Cardiovascular:** Resting tachycardia (fast heart rate), orthostatic \n     hypotension (dizziness upon standing). * **Gastrointestinal:** Gastroparesis (stomach paralysis/delayed emptying), \n     constipation, or diarrhea. * **Urogenital:** Erectile dysfunction, bladder retention/leakage. * **Hypoglycemia Unawareness:** Loss of the \"warning signs\" (shaking, \n     sweating) of low blood sugar. C. Proximal Neuropathy (Diabetic Amyotrophy)\n   * Affects nerves in the thighs, hips, buttocks, or legs. * Symptoms: Sudden, severe pain in the hip/thigh, followed by weak thigh \n     muscles. D. Focal Neuropathy (Mononeuropathy)\n   * Damage to a specific single nerve (e.g., wrist, head, torso). * Example: Carpal tunnel syndrome or Bell's palsy. 4."
  },
  {
    "chunk_id": "neuropathy_overview__chunk1",
    "source_file": "data\\neuropathy_overview.txt",
    "title": "FILENAME: neuropathy_overview.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "DIAGNOSIS\n-----------------------------------------------------------------------------\n* **Filament Test:** Using a soft nylon fiber (monofilament) to test skin \n  sensitivity on the feet. * **Vibration Testing:** Using a tuning fork to test deep tissue sensation. * **Nerve Conduction Studies (EMG):** Measuring the speed of electrical \n  signals through the nerves. 5. MANAGEMENT & TREATMENT\n-----------------------------------------------------------------------------\n* **Strict Glucose Control:** The only way to stop the progression. * **Pain Management:**\n  - Standard painkillers (NSAIDs) are usually ineffective for nerve pain. - First-line agents: Anti-seizure medications (Pregabalin, Gabapentin) or \n    Antidepressants (Duloxetine) which dampen nerve signaling. * **Foot Care:** Daily inspection is critical to prevent amputation. -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "prediabetes_prevention__chunk0",
    "source_file": "data\\prediabetes_prevention.txt",
    "title": "FILENAME: prediabetes_prevention.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: prediabetes_prevention.txt\nSUBJECT: Protocol for Reversing Prediabetes\nSOURCE: National Diabetes Prevention Program (National DPP)\nGOAL: Return HbA1c to <5.7% via Lifestyle Intervention\n\n1. THE CORE OBJECTIVE: 5-7% WEIGHT LOSS\n-----------------------------------------------------------------------------\nThe National DPP study proved that lifestyle changes are *more* effective than \nmedication (metformin) for preventing diabetes in the long run. * **The Magic Number:** Losing just 5% to 7% of your starting body weight. * **The Math:**\n    -   If you weigh 200 lbs (90 kg) -> Loss Goal: 10 to 14 lbs (4.5 - 6 kg). -   If you weigh 250 lbs (113 kg) -> Loss Goal: 12 to 18 lbs (5.5 - 8 kg). * **Why it Works:** This specific amount of weight loss preferentially targets \n    visceral fat (liver/pancreas fat), which drastically reduces insulin \n    resistance. 2. NUTRITIONAL STRATEGY: THE PLATE METHOD\n-----------------------------------------------------------------------------\nYou do not need to cut out carbs entirely, but you must change the proportion. Visualize your dinner plate as a pie chart. A. 50% Non-Starchy Vegetables (The Base)\n   * *Examples:* Spinach, broccoli, peppers, cauliflower, green beans. * *Mechanism:* High fiber slows gastric emptying, preventing blood sugar \n       spikes. B. 25% Lean Protein (The Satiety Factor)\n   * *Examples:* Chicken, turkey, fish, tofu, beans, eggs. * *Mechanism:* Protein does not raise blood glucose and keeps you full \n       longer, reducing snacking urges. C. 25% Carbohydrate Foods (The Fuel)\n   * *Examples:* Brown rice, oats, quinoa, sweet potato, whole grain bread. * *The Shift:* Switch from \"White\" (refined) to \"Brown\" (complex). Complex \n       carbs take longer to break down into glucose. D. Water (The Beverage)\n   * Eliminate \"Liquid Sugar\" (soda, juice, sweet tea). This is the single \n       fastest way to lower A1C. 3. PHYSICAL ACTIVITY PROTOCOL\n-----------------------------------------------------------------------------\n* **Target:** 150 minutes per week (e.g., 30 mins x 5 days). * **Intensity:** Moderate (Can talk, but can't sing). * **The Mechanism (Why it reverses Prediabetes):**\n    -   Normally, insulin opens the door for sugar to enter muscle cells. -   During exercise, muscle contractions activate **AMPK**, which moves \n        glucose transporters (GLUT4) to the surface *without* needing insulin. -   *Result:* You lower blood sugar even if you are insulin resistant. 4. BEHAVIORAL TACTICS\n-----------------------------------------------------------------------------\nA. Tracking (Self-Monitoring)\n   * Keep a food log (app or paper). People who track what they eat lose \n       twice as much weight as those who don't. B."
  },
  {
    "chunk_id": "prediabetes_prevention__chunk1",
    "source_file": "data\\prediabetes_prevention.txt",
    "title": "FILENAME: prediabetes_prevention.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "Sleep Hygiene\n   * **Goal:** 7-8 hours per night. * **Mechanism:** Sleep deprivation increases **Ghrelin** (hunger hormone) \n       and cortisol, driving cravings for high-sugar foods. C. Stress Management\n   * Chronic stress keeps Cortisol levels high. Cortisol signals the liver \n       to dump glucose into the blood (fighting the \"fight or flight\" response). * *Action:* Deep breathing or meditation lowers cortisol and blood sugar. 5. WHEN TO RETEST\n-----------------------------------------------------------------------------\n* Schedule a follow-up A1C test in **3 to 6 months**. * It takes ~3 months for red blood cells to turnover, so testing sooner \n    won't show the full picture. -----------------------------------------------------------------------------\nEND OF FILE"
  },
  {
    "chunk_id": "pubmed_diabetes_review1__chunk0",
    "source_file": "data\\pubmed_diabetes_review1.txt",
    "title": "FILENAME: pubmed_diabetes_review1.txt",
    "author": "",
    "date": "2024",
    "url": "",
    "text": "FILENAME: pubmed_diabetes_review1.txt\nSOURCE: PubMed (National Library of Medicine)\nTITLE: Pathophysiology and Emerging Therapeutic Strategies in Type 2 Diabetes: A 2024 Update\nJOURNAL: J Clin Endocrinol Metab. 2024 Mar; 109(3): 88-102.\nTYPE: Review Article\n\nABSTRACT\n-----------------------------------------------------------------------------\nBACKGROUND: \nType 2 Diabetes Mellitus (T2DM) is a complex, multifactorial metabolic \ndisorder characterized by chronic hyperglycemia, insulin resistance, and \nprogressive beta-cell failure. While traditional models focused primarily on \nthe \"triumvirate\" of muscle, liver, and beta-cell dysfunction, recent \nevidence suggests a much broader pathophysiological basis, often referred to \nas the \"Ominous Octet.\" This review examines the latest advances in understanding \nthese mechanisms and their implications for modern pharmacotherapy.\n\nMETHODS: \nWe conducted a comprehensive search of PubMed and EMBASE for high-impact \nreviews and clinical trials published between 2020 and 2024. Emphasis was \nplaced on the role of the gut microbiome, incretin defects, and renal glucose \nhandling.\n\nRESULTS: \nCurrent research highlights that hyperglycemia in T2DM is driven by defects \nin at least eight distinct organs: (1) decreased insulin secretion (pancreas), \n(2) decreased incretin effect (gut), (3) increased lipolysis (fat), (4) \nincreased glucose reabsorption (kidney), (5) increased hepatic glucose \nproduction (liver), (6) neurotransmitter dysfunction (brain), (7) muscle \ninsulin resistance, and (8) elevated glucagon secretion (alpha-cells). \nTherapeutic agents such as SGLT-2 inhibitors and GLP-1 receptor agonists \naddress these defects more comprehensively than older agents like sulfonylureas.\n\nCONCLUSION: \nThe management of T2DM has shifted from a \"glucocentric\" approach (lowering \nsugar) to a \"cardio-renal-metabolic\" approach. Early combination therapy \ntargeting multiple pathophysiological pathways is now recommended to preserve \nbeta-cell function and reduce long-term cardiovascular mortality."
  },
  {
    "chunk_id": "pubmed_metabolic_syndrome__chunk0",
    "source_file": "data\\pubmed_metabolic_syndrome.txt",
    "title": "FILENAME: pubmed_metabolic_syndrome.txt",
    "author": "",
    "date": "2023",
    "url": "",
    "text": "FILENAME: pubmed_metabolic_syndrome.txt\nSOURCE: PubMed (National Library of Medicine)\nTITLE: Metabolic Syndrome: Epidemiology, Pathophysiology, and Cardiovascular Risk\nJOURNAL: Lancet Diabetes Endocrinol. 2023 Nov; 11(11): 725-738.\nTYPE: Systematic Review\n\nABSTRACT\n-----------------------------------------------------------------------------\nBACKGROUND: \nMetabolic Syndrome (MetS) represents a clustering of cardiovascular risk \nfactors that includes central obesity, dyslipidemia, hypertension, and \nhyperglycemia. Its prevalence is rising globally, paralleling the obesity \nepidemic. This review aims to define the clinical criteria and quantify the \nexcess risk for Cardiovascular Disease (CVD) and Type 2 Diabetes (T2DM).\n\nMETHODS: \nA systematic review of epidemiological data from the NHANES and WHO databases \nwas performed. We analyzed studies linking insulin resistance to the \ndevelopment of atherosclerotic plaques and endothelial dysfunction.\n\nRESULTS: \nMetabolic Syndrome is generally defined by the presence of three or more of \nthe following five criteria: (1) Waist circumference >102cm (men) or >88cm \n(women); (2) Triglycerides \u2265150 mg/dL; (3) HDL cholesterol <40 mg/dL (men) \nor <50 mg/dL (women); (4) Blood pressure \u2265130/85 mmHg; (5) Fasting glucose \n\u2265100 mg/dL. Individuals with MetS have a 2-fold increase in the risk of CVD \nand a 5-fold increase in the risk of developing T2DM compared to those \nwithout the syndrome. The central driver appears to be insulin resistance, \nwhich triggers an inflammatory and pro-thrombotic state.\n\nCONCLUSION: \nMetS is a critical public health warning sign. Identifying patients with \nthis cluster of risk factors allows for early lifestyle intervention. \nWeight loss of 5-10% remains the primary therapeutic intervention to \nreverse the underlying insulin resistance and mitigate cardiovascular risk."
  },
  {
    "chunk_id": "pubmed_obesity_link__chunk0",
    "source_file": "data\\pubmed_obesity_link.txt",
    "title": "FILENAME: pubmed_obesity_link.txt",
    "author": "",
    "date": "2023",
    "url": "",
    "text": "FILENAME: pubmed_obesity_link.txt\nSOURCE: PubMed (National Library of Medicine)\nTITLE: Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes\nJOURNAL: Nature Reviews Endocrinology. 2023; 19: 345\u2013360.\nTYPE: Review\n\nABSTRACT\n-----------------------------------------------------------------------------\nBACKGROUND: \nThe strong association between obesity and Type 2 Diabetes (T2DM) has led to \nthe coinage of the term \"Diabesity.\" However, not all obese individuals \ndevelop diabetes, and the molecular mechanisms linking excess adipose tissue \nto systemic insulin resistance remain an area of intense study. This review \nfocuses on the \"adipose tissue expandability\" hypothesis and the role of \ninflammation.\n\nMECHANISMS REVIEWED: \n1. **Lipotoxicity:** When subcutaneous adipose tissue reaches its storage \ncapacity, excess lipids spill over into non-adipose tissues (liver, muscle, \npancreas) as Ectopic Fat. This leads to the accumulation of toxic lipid \nmetabolites (ceramides, diacylglycerol) that interfere with insulin signaling \npathways.\n2. **Adipokines:** Adipose tissue functions as an endocrine organ. In obesity, \nit shifts from secreting insulin-sensitizing hormones (Adiponectin) to \npro-inflammatory cytokines (TNF-alpha, IL-6, Resistin).\n3. **Macrophage Infiltration:** Hypertrophic adipocytes attract immune cells \n(macrophages), leading to a chronic state of low-grade inflammation that \nperpetuates systemic insulin resistance.\n\nCONCLUSION: \nVisceral adiposity acts as a pathogenic depot that drives metabolic dysfunction \nthrough lipotoxicity and inflammation. Therapeutic strategies that specifically \ntarget visceral fat reduction or improve adipose tissue function may offer \nnovel avenues for preventing the progression from obesity to T2DM."
  },
  {
    "chunk_id": "sglt2_inhibitors__chunk0",
    "source_file": "data\\sglt2_inhibitors.txt",
    "title": "FILENAME: sglt2_inhibitors.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: sglt2_inhibitors.txt\nSUBJECT: Sodium-Glucose Cotransporter-2 Inhibitors\nCLASS: Gliflozins\nBRANDS: Jardiance (Empagliflozin), Farxiga (Dapagliflozin), Invokana (Canagliflozin)\n\n1. MECHANISM OF ACTION (THE \"DRAIN\" EFFECT)\n-----------------------------------------------------------------------------\n* **Normal Physiology:** The kidneys filter glucose but reabsorb 90% of it back into the blood via the SGLT2 protein.\n* **Drug Action:** Blocks this reabsorption.\n* **Result:** Excess glucose is excreted in the urine (Glucosuria).\n    * *Caloric Loss:* Losing sugar in urine leads to weight loss (~200-300 kcal/day).\n\n2. KEY BENEFITS (BEYOND GLUCOSE)\n-----------------------------------------------------------------------------\n* **Cardio-Protective:** Significantly reduces risk of hospitalization for Heart Failure.\n* **Renal-Protective:** Reduces pressure in the glomerulus, preserving kidney function.\n\n3. SIDE EFFECTS\n-----------------------------------------------------------------------------\n* **Genital Yeast Infections:** Sugar in urine feeds bacteria/yeast.\n* **Dehydration/Hypotension:** Acts as a diuretic (increases urination).\n* **DKA:** Rare risk of \"Euglycemic DKA\" (DKA with normal blood sugar)."
  },
  {
    "chunk_id": "sick_day_management__chunk0",
    "source_file": "data\\sick_day_management.txt",
    "title": "FILENAME: sick_day_management.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: sick_day_management.txt\nSUBJECT: Managing Diabetes During Illness/Infection\nRISK: Stress Hormones elevate Glucose\n\n1. THE PHYSIOLOGY OF ILLNESS\n-----------------------------------------------------------------------------\nWhen sick (flu, infection, fever), the body releases stress hormones (cortisol, epinephrine). These hormones cause the liver to release glucose to fight the illness, causing blood sugar to spike, even if the patient isn't eating.\n\n2. THE PROTOCOL\n-----------------------------------------------------------------------------\n* **Never Stop Insulin:** Even if you are vomiting and can't eat, your body needs basal insulin to prevent DKA.\n* **Frequent Testing:** Check glucose every 2\u20134 hours.\n* **Ketone Testing:** Check urine/blood for ketones if glucose >240 mg/dL.\n* **Hydration:** Drink 8oz of sugar-free fluid every hour.\n\n3. WHEN TO CALL THE DOCTOR\n-----------------------------------------------------------------------------\n* Vomiting/Diarrhea for more than 6 hours.\n* Moderate to large ketones in urine.\n* Blood glucose stays >250 mg/dL despite extra insulin."
  },
  {
    "chunk_id": "type2_risk_factors__chunk0",
    "source_file": "data\\type2_risk_factors.txt",
    "title": "FILENAME: type2_risk_factors.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "FILENAME: type2_risk_factors.txt\nSUBJECT: Comprehensive Risk Profile for Type 2 Diabetes (T2DM)\nCATEGORIES: Modifiable (Lifestyle), Non-Modifiable (Genetic/Biologic), and Medical History\n\n1. NON-MODIFIABLE RISK FACTORS (BIOLOGICAL HARDWIRING)\n-----------------------------------------------------------------------------\nThese factors determine your baseline genetic susceptibility. A. Genetics and Family History\n   * **Risk:** Having a first-degree relative (parent or sibling) with T2DM increases risk by 2-6x. * **Mechanism:** Genetic variants (e.g., TCF7L2 gene) affect beta-cell function (insulin production) and insulin sensitivity. B. Ethnicity / Race\n   * **High-Risk Groups:** African American, Hispanic/Latino, Native American, and Asian American populations. * **Mechanism:** - **\"Thrifty Genotype\" Hypothesis:** Evolutionary adaptation to store fat efficiently for times of famine, which backfires in modern caloric abundance. - **Visceral Adiposity:** Asian populations, specifically, tend to store visceral fat at lower BMIs (\"Skinny Fat\"), leading to insulin resistance despite normal weight. C. Age\n   * **Risk:** Risk increases significantly after age 45 (though onset is appearing younger). * **Mechanism:** - Mitochondrial efficiency declines with age (reduced energy burning). - Pancreatic beta-cells gradually \"burn out\" and secrete less insulin over decades. 2. MODIFIABLE RISK FACTORS (LIFESTYLE DRIVERS)\n-----------------------------------------------------------------------------\nThese are the primary drivers of the current global epidemic. A. Obesity and Weight Distribution\n   * **BMI Thresholds:** BMI \u2265 25 kg/m\u00b2 (general) or \u2265 23 kg/m\u00b2 (Asian Americans). * **Central Obesity (The Critical Factor):**\n     - Men: Waist circumference > 40 inches. - Women: Waist circumference > 35 inches. * **Mechanism (Lipotoxicity):** Visceral fat (belly fat) is not inert storage; it is an active endocrine organ. It releases Free Fatty Acids (FFAs) and inflammatory cytokines (TNF-\u03b1, IL-6) that directly block insulin signaling in muscle and liver. B. Sedentary Lifestyle\n   * **Risk:** Physical activity less than 3 times/week. * **Mechanism:** - Muscle contraction stimulates glucose uptake *independently* of insulin (via AMPK pathway). - Inactivity leads to downregulation of GLUT4 transporters, making cells \"deaf\" to insulin signals. C. Diet (The Western Pattern)\n   * **Risk:** High intake of sugar-sweetened beverages, refined grains, and processed meats. * **Mechanism:**\n     - **Glycemic Load:** Constant spikes in blood sugar force the pancreas to hyper-secrete insulin, eventually leading to beta-cell exhaustion. - **Fructose:** High fructose intake drives hepatic (liver) fat accumulation (Fatty Liver), a root cause of insulin resistance. 3. MEDICAL HISTORY & METABOLIC MARKERS\n-----------------------------------------------------------------------------\nExisting conditions that serve as \"warning lights\" for future diabetes. A."
  },
  {
    "chunk_id": "type2_risk_factors__chunk1",
    "source_file": "data\\type2_risk_factors.txt",
    "title": "FILENAME: type2_risk_factors.txt",
    "author": "",
    "date": "",
    "url": "",
    "text": "Prediabetes\n   * **Definition:** HbA1c 5.7% \u2013 6.4%. * **Significance:** Indicates that insulin resistance is already established; beta-cell function may already be reduced by ~50%. B. Gestational Diabetes (GDM)\n   * **Risk:** History of diabetes during pregnancy or delivering a baby >9 lbs. * **Significance:** Women with GDM have a ~50% lifetime risk of developing T2DM. It unmasks an underlying metabolic fragility. C. Polycystic Ovary Syndrome (PCOS)\n   * **Mechanism:** PCOS is fundamentally a state of insulin resistance. High insulin levels stimulate the ovaries to produce excess testosterone. D. Hypertension & Dyslipidemia\n   * **The \"Deadly Quartet\":** High Blood Pressure (>130/80), High Triglycerides (>250 mg/dL), and Low HDL (<35 mg/dL) often cluster with High Blood Sugar. This cluster is known as **Metabolic Syndrome**. 4. EMERGING RISK FACTORS\n-----------------------------------------------------------------------------\n* **Sleep Apnea:** Chronic intermittent hypoxia (oxygen deprivation) during sleep triggers a stress response (cortisol release), which spikes blood sugar. * **Smoking:** Nicotine directly increases insulin resistance and abdominal fat accumulation. * **Chronic Stress:** Persistently elevated cortisol stimulates the liver to produce glucose (gluconeogenesis), keeping blood sugar artificially high. -----------------------------------------------------------------------------\nEND OF FILE"
  }
]